Equity Profile

NVS

Novartis AG

Health CarePharmaceuticals$288.4B

Jul21Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Novartis AG (NVS) is a global healthcare company that focuses on developing and manufacturing innovative pharmaceuticals. With a market cap of $288 billion, it plays a significant role in the healthcare sector, addressing various medical needs through its diverse product portfolio.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and market share, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NVS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.66%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q1-2026, Novartis reported an EPS of $1.99, falling short of the expected $2.11, resulting in a 5.6% surprise. The stock reacted positively the next day, gaining 0.91%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Novartis are mixed, with investors looking for clarity on earnings and future growth potential. The company has a history of beating EPS estimates, but recent performance has raised concerns.

Bull Case

If Novartis can demonstrate strong revenue growth and positive updates on its drug pipeline, it may boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company reports disappointing earnings or lacks clarity on future growth, it could lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated outlook on the drug pipeline and any new product launches?

The market will closely evaluate any new developments that could impact future revenue and growth potential.

How does management plan to address the recent EPS miss and what steps are being taken to improve performance?

Investors will be looking for reassurance and strategies to enhance profitability following a disappointing earnings report.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Novartis to rebound with strong pipeline updates and improved operational efficiency.

Supporting Evidence

Options are pricing a 9.59% move, indicating higher uncertainty than historical averages.

The company's history shows a 75% EPS beat rate, suggesting potential for positive surprises.

Recent stock performance indicates resilience despite earnings misses.

Key Risk

If the drug pipeline shows significant advancements, it could dramatically shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in determining whether Novartis can regain investor confidence after recent misses.

Bull Confirmed If

Strong revenue growth of over 5% year-over-year would confirm the bull case.

Bear Confirmed If

An EPS below $1.90 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.59%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move of nearly 10%, indicating uncertainty or anticipation around the earnings report.

Options are pricing ±9.6% while NVS has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

20.0%

Calls (11K)P/C Ratio: 1.10Puts (8K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novartis beats expectations, history suggests the stock could rise by around 2.5%, confirming a positive outlook.

In-Line / Cautious

A cautious in-line report may lead to minimal movement, as investors await further clarity on future growth.

Miss

If the company misses expectations, the stock could drop by approximately 1.8%, reflecting ongoing concerns about its performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any new product approvals.
2Management's strategy for addressing the recent EPS miss.
3Insights into revenue growth expectations for the upcoming quarters.
4Any commentary on market competition and positioning.
5Plans for cost management and operational efficiency improvements.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ICICI Bank Limited

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and market share, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NVS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.66%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q1-2026, Novartis reported an EPS of $1.99, falling short of the expected $2.11, resulting in a 5.6% surprise. The stock reacted positively the next day, gaining 0.91%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Novartis can demonstrate strong revenue growth and positive updates on its drug pipeline, it may boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company reports disappointing earnings or lacks clarity on future growth, it could lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated outlook on the drug pipeline and any new product launches?

The market will closely evaluate any new developments that could impact future revenue and growth potential.

How does management plan to address the recent EPS miss and what steps are being taken to improve performance?

Investors will be looking for reassurance and strategies to enhance profitability following a disappointing earnings report.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Novartis to rebound with strong pipeline updates and improved operational efficiency.

Supporting Evidence

Options are pricing a 9.59% move, indicating higher uncertainty than historical averages.

The company's history shows a 75% EPS beat rate, suggesting potential for positive surprises.

Recent stock performance indicates resilience despite earnings misses.

Key Risk

If the drug pipeline shows significant advancements, it could dramatically shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in determining whether Novartis can regain investor confidence after recent misses.

Bull Confirmed If

Strong revenue growth of over 5% year-over-year would confirm the bull case.

Bear Confirmed If

An EPS below $1.90 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.59%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move of nearly 10%, indicating uncertainty or anticipation around the earnings report.

Options are pricing ±9.6% while NVS has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

20.0%

Calls (11K)P/C Ratio: 1.10Puts (8K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novartis beats expectations, history suggests the stock could rise by around 2.5%, confirming a positive outlook.

In-Line / Cautious

A cautious in-line report may lead to minimal movement, as investors await further clarity on future growth.

Miss

If the company misses expectations, the stock could drop by approximately 1.8%, reflecting ongoing concerns about its performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any new product approvals.
2Management's strategy for addressing the recent EPS miss.
3Insights into revenue growth expectations for the upcoming quarters.
4Any commentary on market competition and positioning.
5Plans for cost management and operational efficiency improvements.